Holen Sie sich die Stockscreener-App
189.24
0.92%
1.73
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines director Sushil Patel sells $1.05m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 July By Investing.com - Investing.com Canada
Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options - Stock Titan
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. - Yahoo Finance
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
8-Day Rally Sends Revolution Medicines Stock Up 23% - Trefis
Price to earnings forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines Price Target Raised to $235.00/Share From $183.00 by Needham - Moomoo
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Proposed sale of RVMD common shares reported (NASDAQ: RVMD) - Stock Titan
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Growth Benchmark - marketscreener.com
Price to sales forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
RVMD Maintained by Needham -- Price Target Raised to $235 - GuruFocus
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces - GlobeNewswire
Revolution Medicines Is Maintained at Buy by Needham - Moomoo
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 3000E Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 1000 Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) dropped from Russell 2500 Index - marketscreener.com
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – TRADEGATE:42Z - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Insider Sell: Jack Anders Sells 20,000 Shares of Revolution Medi - GuruFocus
42Z Forecast — Price Target — Prediction for 2027 - TradingView
Revolution Medicines (RVMD) CFO trades 20K shares under 10b5-1 plan - Stock Titan
Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says - Moomoo
RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $182 - Moomoo
Revolution Medicines, Inc. Actuals & Estimates (NASDAQ:RVMD) - TradingView
Revolution Medicines, Inc. Actuals & Estimates (BMV:RVMD) - TradingView
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $188.57, Implies 11% Upside - TradingView
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Erasca, Inc. (ERAS) to Contact Law Firm - StreetInsider
Revolution Medicines, Inc. Actuals & Estimates (LSX:A2PYWG) - TradingView
Revolution Medicines rises as investors focus on fresh pancreatic cancer pipeline updates - Quiver Quantitative
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $200 - Moomoo
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $212 - Moomoo
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines to Present Four RAS(ON) Pipeline Studies at 2026 ESMO Gastrointestinal Cancers Congress - Quiver Quantitative
Revolution Medicines to Present Clinical Data from RAS(ON) - GlobeNewswire
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - Yahoo! Finance Canada
Form 144 Revolution Medicines For: 24 June By Investing.com - Investing.com Nigeria
A pancreatic cancer drug provides new hope: Five things to know about daraxonrasib - Stanford Medicine
Form 144 | Revolution Medicines(RVMD.US) Officer Proposes to Sell 3.39 Million in Common Stocks - Moomoo
Jack Anders (RVMD) files to sell 20,000 shares after option exercise - Stock Titan
Enterprise value to EBIT forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
'A Watershed Moment': Revolution Medicines Chief Development Officer Dr. Alan Sandler On The Breakthrough Giving New Hope in Pancreatic Cancer - SurvivorNet
Enterprise value to revenue forward of Revolution Medicines, Inc. – TRADEGATE:42Z - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer - Sahm
Form 4 Revolution Medicines Inc For: 23 June By Investing.com - Investing.com Nigeria
Revolution Medicines (RVMD) grants stock options and RSUs to director - Stock Titan
Revolution Medicines (RVMD) director receives stock awards and options grant - Stock Titan
Revolution Medicines (RVMD) director granted RSUs and stock options in latest Form 4 - Stock Titan
Revolution Medicines (RVMD) director receives new stock and option grants - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director receives stock and 3,127-share option grant - Stock Titan
3.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):